Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Law, M. R. Articles by Soumerai, S. B. Search for Related Content PubMed Citation Articles by Law, M. R. Articles by Soumerai, S. B. Costs, Cost Analysis Social Security, Other Entitlements Atypical Neuroleptics Related Article

Effect of Prior Authorization of Second-Generation Antipsychotic Agents on Pharmacy Utilization and Reimbursements

OBJECTIVE: Medicaid expenditures for antipsychotic medications have risen rapidly, from under $1.0 billion in 1995 to over $5.5 billion in 2005. In response, at least ten states have implemented prior-authorization programs that restrict access to particular second-generation antipsychotic agents (aripiprazole and olanzapine). Twenty-two states restrict particular dosing forms (injections). This study examined the impact of such restrictions. METHODS: The authors used interrupted time-series analysis of quarterly state-level drug utilization data to examine the impact of prior authorization for particular agents in West Virginia and Texas. Changes in market share of nonpreferred medications and total pharmacy costs were compared with changes in states without similar prior-authorization requirements. RESULTS: The West Virginia policy led to an immediate 3.5% reduction in market share level (p<.01) and a 1.3% decrease in trend per quarter in market share (p<.001) for nonpreferred antipsychotics, leading to a 13.9% reduction after two years. In Texas, prior authorization reduced the market share level of nonpreferred agents by 2.6% (p=.055). However, prior authorization did not lead to a significant decrease in pharmacy reimbursements in either state. CONCLUSIONS: Current prior-authorization policies for second-generation antipsychotics do not appear to reduce pharmacy reimbursement, probably because alternative medications are costly. These findings suggest that any cost savings from prior-authorization policies would accrue largely through supplemental rebate agreements with manufacturers, which are likely reduced by the transfer of dually eligible Medicaid enrollees to Medicare Part D plans. Further evaluation of the clinical consequences resulting from such policies is urgently needed to determine whether the minimal cost savings outweigh the potential clinical risks.

Related Article:

May 2008: This Month's Highlights
Psychiatr Serv 2008 59: 475. [Full Text] [PDF]

This article has been cited by other articles:

				M. R. Law, S. B. Soumerai, A. S. Adams, and S. R. Majumdar Costs and Consequences of Direct-to-Consumer Advertising for Clopidogrel in Medicaid Arch Intern Med, November 23, 2009; 169(21): 1969 - 1974. [Abstract] [Full Text] [PDF]

				S. Crystal, M. Olfson, C. Huang, H. Pincus, and T. Gerhard Broadened Use Of Atypical Antipsychotics: Safety, Effectiveness, And Policy Challenges Health Aff., September 1, 2009; 28(5): w770 - w781. [Abstract] [Full Text] [PDF]

				R. A. Rosenheck and M. J. Sernyak Developing A Policy For Second-Generation Antipsychotic Drugs Health Aff., September 1, 2009; 28(5): w782 - w793. [Abstract] [Full Text] [PDF]

				M. Olfson, S. C. Marcus, and G. J. Wan Treatment Patterns for Schizoaffective Disorder and Schizophrenia Among Medicaid Patients Psychiatr Serv, February 1, 2009; 60(2): 210 - 216. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us